Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT versus NAPROXEN AND ESOMEPRAZOLE MAGNESIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT versus NAPROXEN AND ESOMEPRAZOLE MAGNESIUM.
DEXILANT vs NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Esomeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase pump in gastric parietal cells, decreasing gastric acid secretion.
30 mg orally once daily for up to 8 weeks; for healing esophagitis, 60 mg orally once daily for up to 8 weeks; maintenance 30 mg orally once daily.
One tablet (naproxen 500 mg / esomeprazole 20 mg) orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 1–2 hours in healthy subjects, but due to prolonged gastric acid suppression via irreversible binding to proton pumps, duration of action exceeds 24 hours. Half-life is not directly correlated with pharmacodynamic effect.
Naproxen: ~12-17 hours (allows twice-daily dosing). Esomeprazole: ~1-1.5 hours (no accumulation).
Renal (approximately 50% as inactive metabolites) and fecal (approximately 50% as inactive metabolites).
Naproxen: ~95% renal (as unchanged drug and conjugates), ~5% fecal. Esomeprazole: ~80% renal (as metabolites), ~20% fecal.
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor